Vanguard Fiduciary Trust
GYRE icon

Vanguard Fiduciary Trust’s Gyre Therapeutics GYRE Stock Holding History

Vanguard Fiduciary Trust’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$996K Buy
151,073
+13,391
+10% +$91.2K ﹤0.01% 3020
2026
Q1 		$960K Buy
+137,682
New +$1.07M ﹤0.01% 2931

Other funds holding GYRE

HH
HSG Holding Na, Hong Kong $1.2B AUM 23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Fiduciary Trust's GYRE Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Gyre Therapeutics (GYRE) stake by 9.7% in Q2 2026, buying an estimated $91.2K and bringing the position to 151,073 shares worth $996K. The position accounts for ﹤0.01% of the portfolio, ranked #3020.

Vanguard Fiduciary Trust first reported a position in GYRE in Q1 2026 and has held it in 2 quarters since. 60 funds tracked by Wall St. Rank hold GYRE as of Q2 2026.

  • Vanguard Fiduciary Trust held 151,073 shares of Gyre Therapeutics worth $996K as of Q2 2026.
  • Vanguard Fiduciary Trust bought 13,391 Gyre Therapeutics shares in Q2 2026, an estimated $91.2K.
  • Gyre Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3020 holding.
  • Vanguard Fiduciary Trust first reported a position in Gyre Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 60 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.